Evaluation of the highest concentrations used in the in vitro chromosome aberrations assay

Environmental and Molecular Mutagenesis

Volumn 54, Issue 1, 2013, Pages 36-43

  Brookmire, Lauren ^a   Chen, James J ^b   Levy, Dan D ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Cytotoxicity; Genetic toxicity; Regulatory

Indexed keywords

ARTICLE; CHROMOSOME ABERRATION; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); GENOTOXICITY; IN VITRO STUDY; MAMMAL CELL; MONTE CARLO METHOD; NONHUMAN; REFERENCE DATABASE; RELIABILITY; SIMULATION;

ANIMALS; CARCINOGENS; CHROMOSOME ABERRATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; MONTE CARLO METHOD; MUTAGENICITY TESTS; RODENTIA; SENSITIVITY AND SPECIFICITY;

MAMMALIA;

EID: 84871931422     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.21738     Document Type: Article

References (18)

1. Ashby J, Tennant RW. 1991. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat Res 257: 229-306.
2. Clark J, Gudi R, Krsmanovid L, Pant K, Wagner VIII, Witt KL. 2008. Untitled Comments to FDA Docket FDA-2008-D-0178. Available at: http://www.regulations.gov/#!documentDetail;D=FDA-2008-D-0178-0018; Accessed on 2-16-2012.
3. Dearfield KL, Thybaud V, Cimino MC, Custer L, Czich A, Harvey JS, Hester S, Kim JH, Kirkland D, Levy DD, Lorge E, Moore MM, Ouedraogo-Arras G, Schuler M, Suter W, Sweder K, Tarlo K, Van Bentham J, Van Goethem F, Witt KL. 2011. Follow-up actions from positive results of in vitro genetic toxicity testing. Environ Mol Mutagen 52: 177-204.
4. Eastmond DA, Hartwig A, Anderson D, Anwar WA, Cimino MC, Dobrev I, Douglas GR, Nohmi T, Phillips DH, Vickers C. 2009. Mutagenicity testing for chemical risk assessment: Update of the WHO/IPCS Harmonized Scheme. Mutagenesis 24: 341-349.
5. Elespuru RK, Agarwal R, Atrakchi AH, Bigger CA, Heflich RH, Jagannath DR, Levy DD, Moore MM, Ouyang Y, Robison TW, Sotomayor RE, Cimino MC, Dearfield KL. 2009. Current and future application of genetic toxicity assays: The role and value of in vitro mammalian assays. Toxicol Sci 109: 172-179.
6. Fellows MD, Boyer S, O'Donovan MR. 2011. The incidence of positive results in the mouse lymphoma TK assay (MLA) in pharmaceutical screening and their prediction by MultiCase MC4PC. Mutagenesis 26: 529-532.
7. Galloway S, Lorge E, Aardema MJ, Eastmond D, Fellows M, Heflich R, Kirkland D, Levy DD, Lynch AM, Marzin D, Morita T, Schuler M, Speit G. 2011. Workshop summary: Top concentration for in vitro mammalian cell genotoxicity assays; and report from working group on toxicity measures and top concentration for in vitro cytogenetics assays (chromosome aberrations and micronucleus). Mutat Res 723: 77-83.
8. ICH. 2011. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use S2(R1). Available at: http://www.ich.org/ fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/ Step4/S2R1_Step4.pdf; Accessed on 2-16-2012.
9. Ishidate MJr, Harnois MC, Sofuni T. 1988. A comparative analysis of data on the clastogenicity of 951 chemical substances tested in mammalian cell cultures. Mutat Res 195: 151-213.
10. Koch AL. 1966. The logarithm in biology I. Mechanisms generating the log-normal distribution exactly. J Theor Biol 12: 276.
11. Kirkland D, Aardema M, Henderson L, Muller L. 2005. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens. I. Sensitivity, specificity and relative predictivity. Mutat Res 584: 1-256.
12. Kirkland D, Fowler P. 2010. Further analysis of Ames-negative rodent carcinogens that are only genotoxic in mammalian cells in vitro at concentrations exceeding 1 mM, including retesting of compounds of concern. Mutagenesis 25: 539-553.
13. Kirkland D, Pfuhler S, Tweats D, Aardema M, Corvi R, Darroudi F, Elhajouji A, Glatt H, Hastwell P, Hayashi M, Kasper P, Kirchner S, Lynch A, Marzin D, Maurici D, Meunier JR, Muller L, Nohynek G, Parry J, Parry E, Thybaud V, Tice R, Van Bentham J, Vanparys P, White P. 2007. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop. Mutat Res 628: 31-55.
14. Kirkland DJ. 1992. Chromosomal aberration tests in vitro: Problems with protocol design and interpretation of results. Mutagenesis 7: 95-106.
15. Moore MM, Honma M, Clements J, Awogi T, Douglas GR, Van Goethem F, Gollapudi B, Kimura A, Muster W, O'Donovan M, Schoeny R, Wakuri S. 2011. Suitable top concentration for tests with mammalian cells: Mouse lymphoma assay workgroup. Mutat Res 723: 84-86.
16. Morita T, Nagaki T, Fukuda I, Okumura K. 1992. Clastogenicity of low pH to various cultured mammalian cells. Mutat Res 268: 297-305.
17. Parry JM, Parry E, Phrakonkham P, Corvi R. 2010. Analysis of published data for top concentration considerations in mammalian cell genotoxicity testing. Mutagenesis 25: 531-538.
18. Schildcrout JS, Margolin BH, Zeiger E. 1999. Predicting rodent carcinogenicity using potency measures of the in vitro sister chromatid exchange and chromosome aberration assays. Environ Mol Mutagen 33: 59-64.